{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:37:08Z","timestamp":1791988628988,"version":"4.4.0"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2018,9,13]]},"DOI":"10.1001\/jamaoncol.2018.0077","type":"journal-article","created":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T12:33:24Z","timestamp":1521722004000},"page":"e180077","source":"Crossref","is-referenced-by-count":337,"title":["Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma"],"prefix":"10.1001","volume":"4","author":[{"given":"Sandra P.","family":"D\u2019Angelo","sequence":"first","affiliation":[{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York"},{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery","family":"Russell","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center, Tampa, Florida"},{"name":"currently affiliated with Immunocore, Ltd, Conshohocken, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9leste","family":"Lebb\u00e9","sequence":"additional","affiliation":[{"name":"Assistance Publique\u2013H\u00f4pitaux de Paris Dermatology and Centre d\u2019Investigation Clinique, University Paris Diderot Institut National de la Sant\u00e9 et de la Recherche Medicale U976, Saint Louis Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Chmielowski","sequence":"additional","affiliation":[{"name":"Department of Medicine, UCLA (University of California, Los Angeles) Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"Gambichler","sequence":"additional","affiliation":[{"name":"Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Grob","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venerology, and Cutaneous Oncology, Aix-Marseille University, Assistance Publique\u2013H\u00f4pitaux de Marseille, Timone Hospital, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Kiecker","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology, and Allergology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Edmund-Lesser-Haus, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme","family":"Rabinowits","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Terheyden","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Allergology, and Venereology, University of L\u00fcbeck, L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Zwiener","sequence":"additional","affiliation":[{"name":"Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcis","family":"Bajars","sequence":"additional","affiliation":[{"name":"EMD Serono, Billerica, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meliessa","family":"Hennessy","sequence":"additional","affiliation":[{"name":"EMD Serono, Billerica, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard L.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, New Brunswick"},{"name":"currently affiliated with Replimune Inc, Woburn, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"cbr180001r1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejca.2016.10.022","article-title":"Merkel cell carcinoma: epidemiology, prognosis, therapy and unmet medical needs.","volume":"71","author":"Schadendorf","year":"2017","journal-title":"Eur J Cancer"},{"issue":"14","key":"cbr180001r3","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.2217\/fon-2017-0072","article-title":"Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma.","volume":"13","author":"Nghiem","year":"2017","journal-title":"Future Oncol"},{"issue":"19","key":"cbr180001r4","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.2217\/fon-2017-0187","article-title":"Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA.","volume":"13","author":"Cowey","year":"2017","journal-title":"Future Oncol"},{"issue":"9","key":"cbr180001r5","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1002\/cam4.2016.5.issue-9","article-title":"Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma.","volume":"5","author":"Iyer","year":"2016","journal-title":"Cancer Med"},{"issue":"1","key":"cbr180001r6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2326-6066.CIR-13-0034","article-title":"PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival.","volume":"1","author":"Lipson","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"cbr180001r7","article-title":"Immune evasion mechanisms and immune checkpoint inhibition in advanced Merkel cell carcinoma.","author":"Schadendorf","journal-title":"Oncoimmunology"},{"issue":"3","key":"cbr180001r8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/CCO.0000000000000363","article-title":"New developments in the biology and the treatment of metastatic Merkel cell carcinoma.","volume":"29","author":"Terheyden","year":"2017","journal-title":"Curr Opin Oncol"},{"issue":"26","key":"cbr180001r9","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma.","volume":"374","author":"Nghiem","year":"2016","journal-title":"N Engl J Med"},{"key":"cbr180001r10","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2017-CT074","article-title":"Non-comparative, open-label, multiple cohort, phase 1\/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): efficacy and safety in Merkel cell carcinoma (MCC).","author":"Topalian","year":"2017","journal-title":"Cancer Res"},{"issue":"10","key":"cbr180001r11","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"key":"cbr180001r15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40425-017-0310-x","article-title":"Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after =1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.","author":"Kaufman","year":"2018","journal-title":"J Immunother Cancer"},{"key":"cbr180001r12","year":"2017"},{"key":"cbr180001r2","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Merkel Cell Carcinoma, version 1. https:\/\/www.nccn.org\/store\/login\/login.aspx?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mcc.pdf. Updated 2017. Accessed October 19, 2017."},{"key":"cbr180001r13","unstructured":"European Commission approves Bavencio (avelumab) for metastatic Merkel cell carcinoma. Darmstadt, Germany: Merck KGaA and Pfizer Inc; September 21, 2017. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/european_commission_approves_bavencio_avelumab_for_metastatic_merkel_cell_carcinoma. Accessed October 8, 2017."},{"key":"cbr180001r14","unstructured":"Bavencio (avelumab) approved for Merkel cell carcinoma in Japan. Darmstadt, Germany: Merck KGaA and Pfizer Inc; September 21, 2017. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/bavencio_avelumab_approved_for_merkel_cell_carcinoma_in_japan. Accessed October 8, 2017."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2675910","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T12:33:26Z","timestamp":1536842006000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.0077"}},"subtitle":["A Preplanned Interim Analysis of a Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2018,9,13]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.0077","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732887568.793567568","asserted-by":"object"}]},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9,13]]}}}